Biomea Fusion to release Phase I data for oral GLP-1 drug BMF-650
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/22/2026
- Wall St set for lower open as AI jitters rekindle, oil gains
- Brent hits five-month high on escalating Middle East conflict
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
- JPMorgan says AI stock selling may be nearing its limit as positioning resets
Tweet
Share
E-mailGet Alerts BMEA Hot Sheet
Join SI Premium – FREE
Biomea Fusion, Inc. (Nasdaq: BMEA) said it will release results from its Phase I GLP-131 clinical study evaluating BMF-650, an investigational oral small-molecule GLP-1 receptor agonist, on October 13, 2026.
The San Carlos, California-based clinical-stage biopharmaceutical company said its management will host a conference call and webcast at 4:30 p.m. ET to discuss the findings.
BMF-650 is one of two oral small-molecule therapies Biomea Fusion is developing, alongside icovamenib, targeting diabetes and obesity.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Sweetgreen names former Shake Shack culinary exec as new chef
- IBM (IBM) PT Raised to $260 at Truist Securities
- Texas Instruments (TXN) PT Raised to $305 at Truist Securities as 'Cycle continues to strengthen'
Create E-mail Alert Related Categories
Corporate NewsRelated Entities
Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
